AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05896748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine - Injectable Suspension (RPV LA)
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Study NCT05633615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given IV
Study NCT05633615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT05633615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT05633615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT or CT
Study NCT05633615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET-CT or CT
Study NCT05633615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05633615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT05633615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lisocabtagene Maraleucel
Description: Given IV
Study NCT05633615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given IV
Study NCT05633615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT05633615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV
Study NCT05633615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT05633615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT05633615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Given IV
Study NCT05111093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-IM Investigational System implantation
Description: Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
Study NCT05474846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Given by PO
Study NCT05474846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Melatonin
Description: Given by PO
Study NCT05474846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given by PO
Study NCT06268860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab vial injection
Description: Vial solution for SC injection administered on Day 1
Study NCT06268860 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab prefilled syringe
Description: Prefilled syringe solution for SC injection administered on Day 1
Study NCT06374264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-C-014
Description: Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
Study NCT05832723 — intervention group
Intervention type: DEVICE
Intervention: 650 nm low-level red-light
Description: Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
Study NCT06324955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard/common language during induction
Description: The anesthesiologist taking care of the patient will use scripted common/standard language during the induction.
Study NCT06324955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive language during induction
Description: The anesthesiologist taking care of the patient will use scripted positive language during the induction.
Study NCT06549036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Peer Decision Coaching Session for PSA Screening
Description: Veterans in the intervention arm will review the content of the mailed DA, including the values clarification exercise, with the Veteran PDC. Veteran PDC Counseling includes: 1) a structured interview with the patient that focuses on determining his understanding of his prostate cancer risk, his screening options, and his goals and values related to his decision making and 2) role playing exercises to improve SDM skills.
Study NCT06629025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution impedance manometry
Description: High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
Study NCT05861089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: end-tidal CO2 measurement
Description: Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
Study NCT06148753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Health Eternal Renewal Regenerating Face Serum with Royal Jelly and Bee Venom
Description: Face serum containing manuka honey, royal bee jelly, and bee venom.
Study NCT06068153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
Study NCT06068153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
Study NCT03934905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals >200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
Study NCT03934905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals >200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
Study NCT06517758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Hard gelatin capsule
Study NCT06517758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Hard gelatin capsule
Study NCT06681012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
Study NCT06680648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of oxygeninsufflation via working channel of flexible scope
Description: addition of oxygeninsufflation via working channel of flexible scope in order to improve visibility when advancing the flexible scope
Study NCT06680648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no-oxygen insufflation
Description: no-oxygen insufflation added to the flexible scope while advancing it
Study NCT06327542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
Study NCT06625086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convensional exercises
Description: Exercises will be provided to individuals in the Self-Guided Exercise group through a brochure.
Study NCT06625086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercises
Description: Exercises will be administered to individuals with PFPS under the supervision of a physiotherapist.
Study NCT06625086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based exercises
Description: The exercises will be administered to participants through a web-based application.
Study NCT06327542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Group Medical Visits
Description: IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice.
Study NCT05693844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pan-T booster co-expressing MSLN CAR T cell
Description: Starting Dose: 1×10\^6 cells/kg
Study NCT06683807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule
Description: Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe
Study NCT06683807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule
Description: Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
Study NCT05693844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered intravenously at dose of 100-200mg/m2 on day -5
Study NCT05693844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
Study NCT05693844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
Study NCT05436223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19Targeted T Cells Injection
Description: A single dose of predetermined level CAR-positive T cells will be infused.
Study NCT06312553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring
Description: Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring described in study arm
Study NCT06312553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Self Management Education
Description: Standard Diabetes Self Management Education described in study arm
Study NCT06005168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin for Injection
Description: 2 grams or 3 grams based on standard of care or morphomic-based decision
Study NCT05146154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin/Relebactam 1.25g
Description: Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
Study NCT06647849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: centers whose interns receive simulation training in the announcement of early spontaneous miscarriage between the 2 inclusion phases
Description: The simulation training sessions for the announcement consultation are set up directly in the centers participating in the with training arm of the study, after the first phase of patient inclusion. These sessions will take place in situ in the center's maternity ward, and will be run by a single team trained in simulation and announcement.~This team of trainers is identical for all centers randomized in the with training arm, and is made up of two trainers: an obstetrician-gynecologist and a psychologist.
Study NCT06647849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: centers with standard in-house management of spontaneous miscarriage/pregnancy arrested in the emergency department
Description: In the participating centers included in the no training arm, interns will have no specific training in announcement. Patients will receive information concerning the diagnosis of a terminated pregnancy or miscarriage from interns not trained in simulation.~During the course of the study, training in the announcement of a miscarriage will be offered to interns from centers in the no training group.
Study NCT06681974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.
Description: * Establish a regular sleep schedule~* Do not stay in bed longer than our regular sleep schedule.~* Avoid naps during the day~* Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed.~* Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed.~* Follow a healthy bedtime routine~* Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances.
Study NCT06681974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL: program of exercises that will be composed of 4 blocks
Description: the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).
Study NCT06683248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigate sleep deprivation
Description: Sleep deprivation~Devices used:~Dreem band for EEG Actiheart Tobii Eye tracker Blood glucose monitor Blood pressure cuff Mira fertility tracker Galvanic skin response K5: wearable metabolic system Fitbit: wearable technology Withings sleep analyzer Body composition monitor
Study NCT06682598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise training
Description: The subjects will perform one session per day of multicomponent physical exercise training, consisting of strength, power, balance, and walking exercises. The program will have progressive intensity and volume, adapted to the frailty level of the patient. The frailty level will be screened by the Short Physical Performance Battery. Each session will consist of two strength exercises for the upper limbs and one to three for the lower limbs. Also, one exercise for balance, and walking. Participants will be instructed to perform the concentric phase of the movement as fast as possible, since a good quality of movement is maintained, and the eccentric phase in two seconds. An expert researcher will supervise the entire session.
Study NCT06687590 — intervention group
Intervention type: DEVICE
Intervention: Peripheral balloon angioplasty
Description: Serration balloon angioplasty of iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistula
Study NCT06689527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Days 3 to 14: 6 mg/kg vamorolone once daily.
Study NCT06689527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Day 1 and 14: Single doses of 2.5 mg midazolam
Study NCT06689176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrisept® Antimicrobial Wound Lavage
Description: Irrisept® Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device comprised of a 450mL bottle of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP) and an applicator (labeled Irriprobe®). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle. The CHG acts as a preservative to inhibit microbial growth in the solution.
Study NCT06687733 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: adeno-associated viral vector with human phenylalanine hydroxylase gene
Study NCT05965479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
Study NCT05121545 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Pro-GRID
Description: Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
Study NCT05109351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participating to Boost Meal Participation
Description: The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
Study NCT06260761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIPO
Description: minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
Study NCT06260761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
Study NCT06695429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.
Study NCT06686472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.
Study NCT06686472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study NCT06689072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder
Study NCT06689072 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychotherapy
Description: Using psychotherapy in opioid use disorder.